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ABSTRACT
Background: Transfusion-transmitted virus (TTV) is a single-stranded DNA virus. Renal transplant pa-tients have a higher risk of TTV infection. 
Objective: To evaluate the prevalence of TTV and its correlation with post-renal transplantation compli-cations in a population of Iranian patients.
Methods: A cross-sectional study was performed on 120 renal transplant recipients. TTV infection in the peripheral blood samples was detected by semi-nested polymerase chain reaction (semi-nested PCR). Then, the relationship between TTV and renal post-transplant complications was examined.
Results: 34.2% renal transplant recipients were positive for TTV. There was a significant correlation be-tween the presence of TTV and diabetes, acute transplant rejection, and urinary tract infection. We did 
not find any direct correlation between the presence of TTV infection and hypertension, hyperlipidemia, respiratory tract infection, and cytomegalovirus infection.
Conclusion: We found an increased rate of TTV infection in renal transplant recipients associated with post-transplantation complications. TTV may be an important risk factor for some post-renal transplan-tation complications.
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INTRODUCTION
Kidney transplantation, the most effec-tive treatment for chronic renal failure [1], is strongly increasing all over the 
world [2]. Aside from the side effects, which 
the transplantation imposes on patients, the 
side effects of weakened immune system, to 
prevent transplant rejection, faces the patients 
with problems such as different bacterial, fun-
gal and viral infections.
Transfusion-transmitted virus (TTV, or 
torque teno virus) is a nude circular single-
stranded DNA virus discovered by Nishizawa, 
et al, in Japanese patients’ serum with post-
transfusion hepatitis of unknown origin, in 
1997 [3]. TTV is prevalent worldwide preva-
lence. Different studies using sensitive PCR 
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systems indicate high prevalence of TTV [3, 
4].
TTV accompanies with some clinical con-
ditions. For example, TTV prevalence is 
30%–42.9% in hemodialysis patients [5, 6], 
20% in intravenous drug abusers [7], 75% in 
hemophiliacs [8], 46.7% in patients with he-
patocellular carcinoma, 40% in cirrhotic pa-
tients (compared to 36.7% in healthy people) 
[9], 46% in non-AG viral liver infections 
(compared to 12% in healthy people), 48% in 
patients with fulminant hepatitis [10], and 
84.2% in HIV-infected (compared to 63% of 
healthy) people [6]. TTV infection in kidney 
transplant recipients has been significantly 
associated with markers of hepatitis B, C and 
E viral infections and also with the history of 
blood transfusion or organ transplant [11]. It 
is likely that there is a relationship between 
this virus and organ transplantation and its 
complications. The high prevalence of TTV in 
liver [12, 13] and kidney [14] transplants has 
been shown. Although new infections of TTV 
may rarely occur after transplantation [14], 
such prevalence [12] as well as its association 
with transplant complications [15] underline 
the importance of TTV in transplantation. 
This study was designed to further investi-
gate the association between TTV and kid-
ney transplantation and its late complications 
including post-transplant diabetes mellitus 
(PTDM), hyperlipidemia, hypertension, acute 
or chronic graft rejection, respiratory infec-
tion, urinary tract infection (UTI), cytomega-
lovirus (CMV) infection, BK infection, a his-
tory of delayed graft function (DGF), and 
the kind of immunosuppressive prescribed as 
maintenance (cyclosporine, tacrolimus, siro-
limus). Moreover, we studied the association 
between TTV infection with different char-
acteristics of the patients including the extent 
of HLA mismatch, glomerular filtration rate 
(GFR), the rate of creatinine, and having fam-
ily relation with donor. Demonstrating such 
association may introduce the TTV infection 
as one of the risk factors for transplant com-
plications.
MATERIALS AND METHODS
Study Subjects
One-hundred and twenty kidney transplant 
recipients who had been transplanted for at 
least two years were enrolled in this study. 
The study was approved by the Ethics Com-
mittee of Kashan University of Medical Sci-
ences. Written informed consent was obtained 
from all participants and their blood samples 
were evaluated for TTV infection. The rele-
vance of TTV infection with later transplant 
complications including PCR-proven CMV 
infection, diabetes, hyperlipidemia, hyperten-
sion, and biopsy-proven acute and chronic re-
jection, were investigated. Viral, bacterial and 
fungal urinary and respiratory infections were 
confirmed by standard indicators of clinical 
and laboratory diagnostics for all patients.
Blood Sample
Three mL of blood was taken from all partici-
pants two years after transplantation. Total 
DNA was extracted by high pure viral nucleic 
acid kit (Roche, Kit Mannheim, Germany). 
TTV DNA was detected by two nested-PCR 
procedures specific for the detection of se-
quences included in the ORF1 region (N22 
PCR) (outer primers: 1901-1918/2227-2210; in-
ner primers: 1919-1936/2192-2175) and in the 
UTR region untranslated region (UTR PCR) 
(primers NG133/NG147; NG134/NG132) of 
the virus. Amplification reaction on the first 
round was performed with a final volume of 25 
μL containing 2.5 mL DNA, 0.2 mM dNTP, 
3 mM MgCl2, 0.2 mL of each primer sense 
and antisense, and 0.77 nU of Platinum™ Taq 
DNA polymerase. After initial DNA denatur-
ation for 90 sec at 97 °C, amplification was 
done in 35 cycles of 94 °C for 30 sec, 59 °C 
for 30 sec, and 72 °C for 3 min and 30 sec, 
followed by 10 min at 72 °C, as the elonga-
tion time. The second round was performed 
with 1 μL of the first PCR product and 0.5 
U of Platinum™ Taq DNA polymerase. The 
initial DNA denaturation step was done at 94 
°C for 3 min, and then the sample was chased 
by amplification in 30 cycles of 94 °C for 30 
sec, 59 °C for 30 sec, 72 °C for 75 sec, and 7 
min at 72 °C, as the elongation time. Ampli-
fied PCR products obtained after the second 
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round of PCR were run on a gel electropho-
resis using 3% agarose containing ethidium 
bromide. UV trans-illuminator (Promega Inc, 
USA) was used to identify the expected 110-bp 
bands (with reference to the standard molecu-
lar weight) [16].
Statistical Analysis
The quantitative variables were expressed as 
mean±SD. The qualitative variables were ex-
pressed as count and percentage. Independent-
sample Student’s t test was used to compare 
quantitative variables. Qualitative data were 
examined with χ2 test with and without Yate’s 
correction. Multiple binary logistic regression 
analysis was used to identify the independent 
risk factors. A p value <0.05 was considered 
statistically significant.
Table 1: Mean±SD of demographic and laboratory findings in kidney transplant recipients with and without TTV 
infection
Variable TTV Negative(n=79) TTV Positive(n=41) p value 
Age 45.5±12.0 45.2±11.0 0.339
Hemoglobin 11.6±2.1 12.5±2.1 0.739
Potassium 4.4±0.5 4.3±0.4 0.117
Platelet (×103) 191.0±64.6 188.0±59.8 0.758
WBC 8178±3259 7601±2812 0.475
LDL 123.4±44.7 131.1±49.8 0.548
Systolic BP 118±14 119±15 0.945
Diastolic BP 78±9 80±10 0.523
ALT 38.5±18.1 46.2±34.5 0.018
AST 31.9±13.6 32.0±15.1 0.694
Table 2: Frequency (%) of kidney transplant complications, kind of immunosuppressives prescribed and differ-
ent characteristics of the patients stratified by presence or absence of TTV infection
Complication TTV Negative(n=79)
TTV Positive
(n=41) p value
Infection
CMV infection 17 (22%) 17 (42%) 0.021
BK infection 5 (6%) 4 (10%) 0.489
UTI 40 (51%) 32 (78%) 0.006
Respiratory infection 17 (22%) 14 (34%) 0.134
Drug
Cyclosporine 46 (58%) 33 (81%)
0.027Sirolimus 16 (20%) 6 (15%)
Tacrolimus 17 (22%) 2 (5%)
DGF 7 (9%) 18 (44%) <0.001
Mean±SD GFR 51.4±17.3 45.7±16.6 0.082
PTDM 2 (3%) 7(17.1%) 0.007
Mean±SD HLA mismatch 3.7±0.9 3.5±1.0 0.544
Rejection 3 (4%) 24 (59%) <0.001
Cr >1.5 mg/dL 24 (30%) 23 (56%) 0.006
Positive family relation 25 (32%) 9 (22%) 0.293
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RESULTS
We studied 120 recipients (54 women) who 
had undergone kidney transplantation at least 
two years prior to the study. The prevalence of 
TTV infection in kidney transplant recipients 
was 34.2% (95% CI: 25.6%–42.7%). Basic and 
laboratory findings of kidney transplant recip-
ients with or without TTV infection are sum-
marized in Table 1. Except for ALT, we did 
not find any significant differences between 
the two groups.
Table 2 shows the frequency of different com-
plications, prescribed immunosuppressive 
drugs and other characteristics of the patients 
during two years post-transplantation. TTV 
infection had a significant association with 
the complications of PTDM (p=0.007), UTI 
(P=0.006), CMV infection (p=0.021), and 
graft rejection (p<0.001). It had no associa-
tion with other complications such as hyper-
tension, hyperlipidemia, and respiratory tract 
infection. TTV infection had a significant 
(p=0.027) association with prescribed drugs 
too—those who were using tacrolimus had 
lower rates of TTV infection compared to oth-
ers. Serum creatinine levels more than 1.5 mg/
dL (p=0.006) and DGF (p<0.001) were also 
associated with TTV infection.
Multiple binary logistic regression analysis 
showed that the correlation between TTV 
infection and cyclosporine, post-transplant 
rejection, positive family relation, and HLA 
mismatch remained significant after adjusting 
for confounders. Although not found inh uni-
variate analysis, TTV infection was also found 
to have a significant association with family 
relation and HLA mismatch (Table 3).
DISCUSSION
TTV infection has a worldwide distribution 
and is organized in different phylogenetic 
groups [17]. No epidemiological study has yet 
been done on TTV and its complications in 
renal transplant recipients in Iran. Given that 
certain segments of the viral TTV DNA are 
less sensitive to the PCR technique [18, 19], 
we used a reliable PCR technique to determine 
the frequency of TTV DNA in the peripheral 
blood of a group of Iranian renal transplant 
recipients. Actually, the choice of primers used 
in the PCR reaction, to identify the presence 
of TTV, can strongly affect the level of its de-
tection in biological fluids.
We found a prevalence of 34.2% of TTV in-
fection in kidney transplant recipients, which 
was similar to some studies [5, 6]. However, 
there are other studies demonstrating higher 
prevalence of TTV. For example, two Brazil-
ian [20], and Japanese [21] studies reported 
a prevalence of 53.8%, and 66%, respectively. 
Such differences may be due to higher prev-
alence of TTV in their general population. 
Actually, there are different patterns of virus 
spreading in different geographic places. An-
other reason legitimizing such difference is 
different PCR methods used by investigators, 
which may significantly influence the results 
of prevalence studies. And, finally according 
to our results, the kind of immunosuppressive 
drugs used by patients may make such differ-
ences. 
In our study, no significant association was 
found between TTV infection and a wide va-
riety of epidemiological and laboratory vari-
ables including age, hemoglobin level, serum 
potassium, platelet count, white blood cell 
count, serum LDL level, systolic and diastolic 
blood pressure, and AST activity. Similar to 
ours, Takemoto, et al [15], showed no signifi-
cant association between TTV and any con-
sidered epidemiological variables including 
sex, blood transfusions, time of dialysis and 
Table 3: Results of logistic regression model af-
fecting TTV infection
Variables B SE p value
Cyclosporine 1.787 0.811 0.027
Sirolimus 1.679 0.929 0.071
Rejection 3.995 0.771 0.000
Positive family  
relation -1.234 0.610 0.043
HLA mismatch -0.779 0.209 0.000
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the presence of hepatitis B in renal-transplant 
recipients. Importantly, we found significantly 
higher levels of ALT in TTV-infected recipi-
ents. Such liver enzyme abnormalities were 
also reported in TTV-infected patients on he-
modialysis [22], emphasizing the possibility 
of liver dysfunction caused by TTV infection. 
However, in Yokosuka, et al, study [20], the 
existence of TTV had no distinctive correla-
tion with ALT abnormality.
In line with some studies, we also found an 
association between post-transplantation 
complications and TTV infection [23-25]. Al-
though TTV infection may be implicated in 
post-transplant complications, some studies 
have not shown such association in hemodial-
ysis-related complications [6]. Such difference 
may be originated from the pathophysiologic 
entity of complications implicated in each con-
dition.
As it seems foreseeable, the history of blood 
transfusion may be a predictor of TTV in-
fection [6]. However, some studies have not 
shown such association [23, 25]. Abraham, et 
al [26], showed no correlation between TTV 
and its risk factors like transfusions, number 
of hemodialysis sessions and time duration af-
ter transplantation. It means that although the 
transfusion or transplantation may be a con-
ventional route of virus transmission, there 
are other ways for entry of the virus. In this 
case, duration of dialysis and the time after 
transplantation may have no effect on TTV 
infection [23].
Interestingly, TTV infection had a consider-
able relevancy with important complication of 
DGF, graft rejection and PTDM in our study 
and others [23]. Considering rejection as the 
main cause of graft loss, we should pay more 
attention to such virus as an important predic-
tor of graft outcome. Our patients using ta-
crolimus showed less rates of TTV infection. 
Therefore, in the case of drugs used, it seems 
that tacrolimus in better option compared to 
cyclosporine according to TTV infection. 
In conclusion, given that about one-third of 
Iranian renal transplant recipients are infect-
ed with TTV, our results should be confirmed 
by other multicenter studies. These people are 
at more risk for post-transplantation compli-
cations. In this case, we may consider TTV 
screening in routine laboratory studies before 
and after the kidney transplantation.
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